Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BioCorRx (BICX) Accounts Payables (2016 - 2025)

BioCorRx's Accounts Payables history spans 16 years, with the latest figure at $12.4 million for Q3 2025.

  • For Q3 2025, Accounts Payables rose 118.26% year-over-year to $12.4 million; the TTM value through Sep 2025 reached $12.4 million, up 118.26%, while the annual FY2024 figure was $5.6 million, 19.91% up from the prior year.
  • Accounts Payables for Q3 2025 was $12.4 million at BioCorRx, up from $11.8 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $12.4 million in Q3 2025 and bottomed at $1.2 million in Q1 2023.
  • The 5-year median for Accounts Payables is $4.3 million (2023), against an average of $5.1 million.
  • The largest annual shift saw Accounts Payables tumbled 63.19% in 2023 before it surged 318.9% in 2024.
  • A 5-year view of Accounts Payables shows it stood at $3.2 million in 2021, then rose by 22.56% to $3.9 million in 2022, then grew by 18.97% to $4.6 million in 2023, then grew by 19.91% to $5.6 million in 2024, then soared by 122.45% to $12.4 million in 2025.
  • Per Business Quant, the three most recent readings for BICX's Accounts Payables are $12.4 million (Q3 2025), $11.8 million (Q2 2025), and $10.9 million (Q1 2025).